Histiocytoma: Clinical Trials

13 trials for Histiocytoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 recruiting, 1 terminated, 1 withdrawn. 13 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Completed 10, Recruiting 1, Terminated 1, Withdrawn 1
Phase 22Completed 1, Terminated 1

Follow Histiocytoma: new trials by email Literature Review of Histiocytoma trials Research Report on Histiocytoma

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Phase 3RecruitingNational Cancer Institute (NCI)3652024-09-112026-11-18
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Phase 3WithdrawnBoehringer Ingelheim2024-06-272024-07-17
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Olaratumab, Doxorubicin, Placebo - Soft Tissue Sarcoma
Phase 3CompletedEli Lilly and Company5092015-09-142025-07-15
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1402014-08-122026-06-17
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma
Phase 2 / Phase 3TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC1332011-05-012014-08-08
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Phase 3CompletedChildren's Oncology Group5882007-02-052022-04-28
Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma
radiotherapy - Sarcoma
Phase 3CompletedSheffield Teaching Hospitals NHS Foundation Trust2162006-03-012021-03-18
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
conventional surgery, radiation therapy - Sarcoma
Phase 3CompletedAlliance for Clinical Trials in Oncology3702004-08-012016-07-06
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
pegfilgrastim, doxorubicin hydrochloride, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC4552003-04-012014-10-27
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
doxorubicin hydrochloride, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC7801998-01-012012-01-20
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
doxorubicin hydrochloride, etoposide, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3401997-07-012013-09-17
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3401996-04-012012-07-11
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3501995-02-012014-08-08

Narrower conditions

Histiocytoma, Malignant Fibrous (13)  ·  Leiomyosarcoma (11)  ·  Liposarcoma (11)  ·  Sarcoma (11)  ·  Fibrosarcoma (10)  ·  Neurofibrosarcoma (10)  ·  Sarcoma, Synovial (10)  ·  Hemangiosarcoma (9)  ·  Hemangiopericytoma, Malignant (6)  ·  Sarcoma, Alveolar Soft Part (6)  ·  Malignant mesenchymal tumor (5)  ·  Chondrosarcoma, Extraskeletal Myxoid (4)  ·  Rhabdomyosarcoma (4)  ·  Dermatofibrosarcoma (3)  ·  Endometrial Neoplasms (2)

Broader conditions

Neoplasms (13)  ·  Neoplasms by Histologic Type (13)  ·  Neoplasms, Connective Tissue (13)  ·  Neoplasms, Connective and Soft Tissue (13)  ·  Neoplasms, Fibrous Tissue (13)  ·  Neoplasms, Adipose Tissue (11)  ·  Neoplasms, Muscle Tissue (11)  ·  Neoplasms, Nerve Tissue (10)  ·  Nervous System Diseases (10)  ·  Nervous System Neoplasms (10)  ·  Neurofibroma (10)  ·  Neuromuscular Diseases (10)  ·  Peripheral Nervous System Diseases (10)  ·  Peripheral Nervous System Neoplasms (10)

Interventions

Doxorubicin (10)  ·  Ifosfamide (7)  ·  Radiotherapy (5)  ·  Filgrastim (2)  ·  Chemotherapy, Adjuvant (1)  ·  Combined Modality Therapy (1)  ·  Diathermy (1)  ·  Docetaxel (1)  ·  Etoposide (1)  ·  Gemcitabine (1)  ·  Observation (1)  ·  Radiation (1)  ·  Radiotherapy, Conformal (1)  ·  Specimen Handling (1)  ·  Trabectedin (1)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  National Cancer Institute (NCI) (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Boehringer Ingelheim (1)  ·  Children's Oncology Group (1)  ·  Eli Lilly and Company (1)  ·  Sheffield Teaching Hospitals NHS Foundation Trust (1)

Countries

Canada (7)  ·  Germany (6)  ·  United Kingdom (6)  ·  United States (6)  ·  Belgium (5)  ·  Denmark (5)  ·  France (5)  ·  Netherlands (5)  ·  Spain (5)  ·  Austria (4)  ·  Slovakia (4)  ·  Switzerland (4)  ·  Hungary (3)  ·  Poland (3)  ·  Puerto Rico (3)

Top investigators

A.N. Van Geel, MD (1)  ·  Aaron R Weiss (1)  ·  Ian R. Judson, MA, MD, FRCP (1)  ·  James E. Butrynski, MD (1)  ·  Laurence H. Baker, DO, FACOI (1)  ·  Martin Robinson, MD (1)  ·  Nguyen Binh Bui, MD (1)  ·  Paul C. Lorigan, MD (1)  ·  Penella J. Woll, MD, PhD (1)  ·  Peter Pisters, MD (1)  ·  Rolf D. Issels, MD, PhD (1)  ·  Ronald H. Blum, MD (1)  ·  Seth M Pollack (1)  ·  Sheri Spunt, MD (1)

Results publications

PMID 17634494, PMID 20434400, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 28447475, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32259228, PMID 32702309, PMID 32827353, PMID 33548339, PMID 33632930, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 41386267, PMID 42035475

NIH funding

U10CA098543 (2), 2009 (1), 2015 (1), U10CA180820 (1), U10CA180830 (1), U10CA180886 (1)